Showing results (151-160 of 228) with videos related to
Sort By:
Pageof 23
Blood Advances|February 18, 2026
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort StudyJia Ruan, Zhengming Chen, Melissa C Larson, et al.Blood Advances|February 9, 2021
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell ProjectAndrei Shustov, Maria Elena Cabrera, Monica Civallero, et al.Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.Hematological Oncology|September 9, 2022
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma projectCarlos Chiattone, Monica Civallero, Thais Fischer, et al.Blood Advances|April 26, 2022
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2Kerry J Savage, Steven M Horwitz, Ranjana Advani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2015
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell LymphomaMark W Clemens, L Jeffrey Medeiros, Charles E Butler, et al.Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.Pageof 23